Improved patient-reported outcomes with iGlarLixi versus premix BIAsp 30 in people with type 2 diabetes in the SoliMix trial.
William H PolonskyFrancesco GiorginoJulio RosenstockKatherine WhitmireElisheva LewMathieu CoudertAgustina AlvarezCharlie J NichollsRory J McCrimmonPublished in: Diabetes, obesity & metabolism (2022)
In addition to better glycaemic control, weight benefit and less hypoglycaemia, once-daily iGlarLixi provided improved diabetes management, treatment burden and perceived effectiveness versus twice-daily premix BIAsp 30, further supporting iGlarLixi as an advanced treatment option in people with suboptimally controlled T2D on basal insulin plus OADs.